Back to Search Start Over

Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase.

Authors :
Mollard, Lise-Marie
Chauveau, Aurélie
Boyer-Perrard, Françoise
Douet-Guilbert, Nathalie
Houot, Roch
Quintin-Roué, Isabelle
Couturier, Marie-Anne
Dagorne, Anaig
Malou, Mohamed
Le Calloch, Ronan
Luycx, Odile
Thepot, Sylvain
Hunault, Mathilde
Guillerm, Gaelle
Berthou, Christian
Ugo, Valérie
Lippert, Éric
Ianotto, Jean-Christophe
Source :
Leukemia & Lymphoma. Dec2018, Vol. 59 Issue 12, p2812-2820. 9p.
Publication Year :
2018

Abstract

Myeloproliferative neoplasms (MPN) are chronic disorders that can sometimes evolve into accelerated or leukemic phases. We retrospectively identified 122 patients with such blastic phases. The overall median survival was four months: 10.2 months for patients treated with intensive treatments compared to three months for best supportive care (p = .005). Azacytidine, intensive chemotherapies, or allogeneic stem cell transplantation gave the highest median survivals with 9, 10.2, and 19.4 months, respectively. Accelerated phases (AP) had a longer median survival compared to acute leukemia (4.8 months vs. 3.1 months; p = .02). In this retrospective and observational study, we observe that the longest survivals are seen in patients eligible for intensive treatments. Azacytidine shows interesting results in patients non-fit for intensive chemotherapy. Supportive care should probably be restricted to elderly patients and those with unfavorable karyotype. An early diagnosis of AP could also result in a better survival rate. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10428194
Volume :
59
Issue :
12
Database :
Academic Search Index
Journal :
Leukemia & Lymphoma
Publication Type :
Academic Journal
Accession number :
133674365
Full Text :
https://doi.org/10.1080/10428194.2018.1441408